Acadian Asset Management LLC Acadia Pharmaceuticals Inc Transaction History

Acadian Asset Management LLC

$32.2 Billion
Q3 2024

A detailed history of Acadian Asset Management LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 4,156 shares of ACAD stock, worth $68,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,156

Previous 6,884 39.63%

Holding current value

$68,033

Previous $111,000 43.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$15.14 - $19.14 $41,301 - $52,213	-2,728 Reduced 39.63%	4,156 $63,000
Q2 2024 Aug 06, 2024	BUY	$14.62 - $18.42 $100,644 - $126,803	6,884 New	6,884 $111,000
Q4 2023 Feb 13, 2024	SELL	$20.78 - $31.77 $158,011 - $241,579	-7,604 Reduced 85.59%	1,280 $40,000
Q3 2023 Nov 13, 2023	BUY	$20.84 - $33.47 $185,142 - $297,347	8,884 New	8,884 $184,000
Q1 2023 May 11, 2023	BUY	$16.32 - $20.92 $189,768 - $243,257	11,628 New	11,628 $218,000
Q3 2021 Nov 12, 2021	SELL	$15.78 - $24.77 $70,994 - $111,440	-4,499 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$19.4 - $27.42 $62,312 - $88,073	-3,212 Reduced 41.65%	4,499 $110,000
Q1 2021 May 11, 2021	BUY	$25.02 - $54.99 $117,168 - $257,518	4,683 Added 154.66%	7,711 $199,000
Q4 2020 Feb 11, 2021	BUY	$41.04 - $56.79 $89,467 - $123,802	2,180 Added 257.08%	3,028 $162,000
Q3 2020 Nov 09, 2020	SELL	$36.42 - $57.0 $4,989 - $7,809	-137 Reduced 13.91%	848 $35,000
Q2 2020 Aug 12, 2020	BUY	$39.26 - $52.73 $38,671 - $51,939	985 New	985 $48,000

Others Institutions Holding ACAD

# of Institutions

280

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Acadia Pharmaceuticals Inc Transaction History